FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3005541245> ?p ?o ?g. }

• W3005541245 endingPage "44" @default.
• W3005541245 startingPage "39" @default.
• W3005541245 abstract "ABSTRACT BACKGROUND: Hepatitis C virus (HCV) infection is the most common hepatotropic viral infection affecting the patients on maintenance hemodialysis. Treatment of chronic HCV infection in stage 4 and 5 CKD includes a combination of elbasvir/grazoprevir and glecaprevir/pibrentasvir, which are not available in many countries. OBJECTIVE: Hence, we have conducted this study to look for the safety and efficacy of sofosbuvir combination therapy in this difficult to treat population. METHODS: We conducted a single-center, prospective, open-label study in which Stage 5 CKD patients on maintenance hemodialysis with HCV infection. Total of 18 patients was included. sofosbuvir with daclatasvir or ledipasvir was used according to genotype for 12 weeks. HCV RNA, genotype, transient elastography (TE) was considered for every patient. HCV RNA was quantified at 4th week, 12th week and 12 weeks post-treatment to look for sustained virologic response (SVR 12). RESULTS: Infection due to genotype 1 was seen in 12 (66.7%) patients followed by genotype 3 in 4 (22.3%) with each patient of genotype 2 and 5. The median value of HCV RNA was 2,35,000 IU/mL. On TE, all had liver stiffness of <9.4 KPa. All patients had HCV RNA of <15 IU/mL at 4th and 12th week of treatment and 12 weeks post-treatment. No significant change in hemoglobin, eGFR and liver stiffness was observed. CONCLUSION: Full dose sofosbuvir i.e. 400 mg, in combination with NS5A inhibitors daclatasvir or ledipasvir is found to be safe and effective in patients with end stage renal disease, who are on maintenance hemodialysis." @default.
• W3005541245 created "2020-02-24" @default.
• W3005541245 creator A5002628864 @default.
• W3005541245 creator A5005990979 @default.
• W3005541245 creator A5064218017 @default.
• W3005541245 creator A5074194514 @default.
• W3005541245 creator A5085549122 @default.
• W3005541245 creator A5085943571 @default.
• W3005541245 date "2020-02-01" @default.
• W3005541245 modified "2023-10-14" @default.
• W3005541245 title "COMBINED NS5A & NS5B NUCLEOTIDE INHIBITOR THERAPY FOR PATIENTS WITH CHRONIC HEPATITIS C WITH STAGE 5 CHRONIC KIDNEY DISEASE ON HEMODIALYSIS" @default.
• W3005541245 cites W1507841308 @default.
• W3005541245 cites W1561848625 @default.
• W3005541245 cites W1908153784 @default.
• W3005541245 cites W1919553596 @default.
• W3005541245 cites W1960733043 @default.
• W3005541245 cites W1963609816 @default.
• W3005541245 cites W1964387122 @default.
• W3005541245 cites W1970062940 @default.
• W3005541245 cites W1983033439 @default.
• W3005541245 cites W2027203857 @default.
• W3005541245 cites W2028177473 @default.
• W3005541245 cites W2046339229 @default.
• W3005541245 cites W2068062063 @default.
• W3005541245 cites W2071825710 @default.
• W3005541245 cites W2090017875 @default.
• W3005541245 cites W2110395148 @default.
• W3005541245 cites W2128428904 @default.
• W3005541245 cites W2284028703 @default.
• W3005541245 cites W2290250957 @default.
• W3005541245 cites W2296452901 @default.
• W3005541245 cites W2337948451 @default.
• W3005541245 cites W2608263244 @default.
• W3005541245 cites W2761085897 @default.
• W3005541245 cites W2762304914 @default.
• W3005541245 cites W2793357379 @default.
• W3005541245 cites W2885103621 @default.
• W3005541245 cites W4240023758 @default.
• W3005541245 cites W4251547440 @default.
• W3005541245 cites W4323521971 @default.
• W3005541245 doi "https://doi.org/10.1590/s0004-2803.202000000-08" @default.
• W3005541245 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32294734" @default.
• W3005541245 hasPublicationYear "2020" @default.
• W3005541245 type Work @default.
• W3005541245 sameAs 3005541245 @default.
• W3005541245 citedByCount "6" @default.
• W3005541245 countsByYear W30055412452020 @default.
• W3005541245 countsByYear W30055412452021 @default.
• W3005541245 countsByYear W30055412452023 @default.
• W3005541245 crossrefType "journal-article" @default.
• W3005541245 hasAuthorship W3005541245A5002628864 @default.
• W3005541245 hasAuthorship W3005541245A5005990979 @default.
• W3005541245 hasAuthorship W3005541245A5064218017 @default.
• W3005541245 hasAuthorship W3005541245A5074194514 @default.
• W3005541245 hasAuthorship W3005541245A5085549122 @default.
• W3005541245 hasAuthorship W3005541245A5085943571 @default.
• W3005541245 hasBestOaLocation W30055412453 @default.
• W3005541245 hasConcept C126322002 @default.
• W3005541245 hasConcept C159047783 @default.
• W3005541245 hasConcept C2522874641 @default.
• W3005541245 hasConcept C2775999097 @default.
• W3005541245 hasConcept C2776408679 @default.
• W3005541245 hasConcept C2776979040 @default.
• W3005541245 hasConcept C2777103181 @default.
• W3005541245 hasConcept C2778063415 @default.
• W3005541245 hasConcept C2778390639 @default.
• W3005541245 hasConcept C2778986448 @default.
• W3005541245 hasConcept C2780040827 @default.
• W3005541245 hasConcept C2781426373 @default.
• W3005541245 hasConcept C2781463415 @default.
• W3005541245 hasConcept C2908647359 @default.
• W3005541245 hasConcept C71924100 @default.
• W3005541245 hasConcept C90924648 @default.
• W3005541245 hasConcept C99454951 @default.
• W3005541245 hasConceptScore W3005541245C126322002 @default.
• W3005541245 hasConceptScore W3005541245C159047783 @default.
• W3005541245 hasConceptScore W3005541245C2522874641 @default.
• W3005541245 hasConceptScore W3005541245C2775999097 @default.
• W3005541245 hasConceptScore W3005541245C2776408679 @default.
• W3005541245 hasConceptScore W3005541245C2776979040 @default.
• W3005541245 hasConceptScore W3005541245C2777103181 @default.
• W3005541245 hasConceptScore W3005541245C2778063415 @default.
• W3005541245 hasConceptScore W3005541245C2778390639 @default.
• W3005541245 hasConceptScore W3005541245C2778986448 @default.
• W3005541245 hasConceptScore W3005541245C2780040827 @default.
• W3005541245 hasConceptScore W3005541245C2781426373 @default.
• W3005541245 hasConceptScore W3005541245C2781463415 @default.
• W3005541245 hasConceptScore W3005541245C2908647359 @default.
• W3005541245 hasConceptScore W3005541245C71924100 @default.
• W3005541245 hasConceptScore W3005541245C90924648 @default.
• W3005541245 hasConceptScore W3005541245C99454951 @default.
• W3005541245 hasIssue "1" @default.
• W3005541245 hasLocation W30055412451 @default.
• W3005541245 hasLocation W30055412452 @default.
• W3005541245 hasLocation W30055412453 @default.
• W3005541245 hasLocation W30055412454 @default.
• W3005541245 hasOpenAccess W3005541245 @default.
• W3005541245 hasPrimaryLocation W30055412451 @default.

• next